Compare MDGL & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDGL | BEN |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.6B |
| IPO Year | N/A | N/A |
| Metric | MDGL | BEN |
|---|---|---|
| Price | $588.97 | $23.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $580.77 | $23.23 |
| AVG Volume (30 Days) | 268.0K | ★ 3.7M |
| Earning Date | 11-04-2025 | 01-30-2026 |
| Dividend Yield | N/A | ★ 5.53% |
| EPS Growth | N/A | ★ 7.28 |
| EPS | N/A | ★ 0.91 |
| Revenue | $740,640,000.00 | ★ $8,770,700,000.00 |
| Revenue This Year | $435.63 | N/A |
| Revenue Next Year | $52.56 | $5.60 |
| P/E Ratio | ★ N/A | $26.25 |
| Revenue Growth | ★ 864.21 | 3.45 |
| 52 Week Low | $265.00 | $16.25 |
| 52 Week High | $615.00 | $26.08 |
| Indicator | MDGL | BEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.31 | 55.65 |
| Support Level | $578.00 | $23.84 |
| Resistance Level | $615.00 | $24.12 |
| Average True Range (ATR) | 17.87 | 0.40 |
| MACD | -1.99 | -0.03 |
| Stochastic Oscillator | 65.70 | 42.22 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.